Table 3.
The results of subgroup analysis in meta-analysis of OS and DFS/PFS/TTP
| Subgroup | No. of studies | HR (95% CI) | P | Heterogeneity | Model used | ||
|---|---|---|---|---|---|---|---|
| I2 | Ph | ||||||
| OS | Analysis of variable | ||||||
| Multivariate | 28 | 1.47(1.31–1.66) | < 0.001 | 80.60% | < 0.001 | Random | |
| Univariate | 11 | 1.62(1.33–1.99) | < 0.001 | 81.70% | < 0.001 | Random | |
| Ethnicity | |||||||
| Asian | 22 | 1.54(1.32–1.80) | < 0.001 | 89.80% | < 0.001 | Random | |
| non-Asian | 17 | 1.42(1.32–1.53) | 0.063 | 37.00% | 0.063 | Fixed | |
| Tumor stage | |||||||
| I-III | 9 | 1.52(1.22–1.89) | < 0.001 | 89.00% | < 0.001 | Random | |
| III-IV | 8 | 1.70(1.26–2.29) | < 0.001 | 85.80% | < 0.001 | Random | |
| I-IV | 15 | 1.37(1.26–1.49) | 0.066 | 38.20% | 0.066 | Fixed | |
| Histology | |||||||
| NSCLC | 29 | 1.58(1.38–1.82) | < 0.001 | 89.80% | < 0.001 | Random | |
| SCLC | 2 | 1.64(0.55–4.87) | 0.008 | 85.60% | 0.008 | Random | |
| NSCLC+SCLC | 8 | 1.39(1.14–1.70) | 0.036 | 53.40% | 0.036 | Random | |
| cut-off value | |||||||
| <300 × 10^9/L | 7 | 1.64(1.25–2.15) | 0.024 | 58.80% | 0.024 | Random | |
| 300 × 10^9/L ≤ cut-off value<400 × 10^9/L | 18 | 1.40(1.27–1.55) | 0.002 | 55.40% | 0.002 | Random | |
| ≥400 × 10^9/L | 13 | 1.73(1.35–2.21) | < 0.001 | 77.90% | < 0.001 | Random | |
| Quality score | |||||||
| > 6 | 23 | 1.59(1.36–1.85) | < 0.001 | 91.20% | < 0.001 | Random | |
| ≤6 | 16 | 1.30(1.19–1.41) | 0.015 | 48.60% | 0.015 | Fixed | |
| DFS/PFS/TTP | Analysis of variable | ||||||
| Multivariate | 7 | 1.66(1.14–2.42) | < 0.001 | 84.40% | < 0.001 | Random | |
| Univariate | 6 | 1.63(1.28–2.09) | < 0.001 | 85.50% | < 0.001 | Random | |
| Ethnicity | |||||||
| Asian | 12 | 1.68(1.33–2.12) | < 0.001 | 85.10% | < 0.001 | Random | |
| non-Asian | 1 | – | – | – | – | – | |
| Tumor stage | |||||||
| I-III | 6 | 1.40(1.26–1.55) | 0.097 | 46.30% | 0.097 | Fixed | |
| III-IV | 4 | 1.74(1.09–2.78) | < 0.001 | 92.50% | < 0.001 | Random | |
| Histology | |||||||
| NSCLC | 12 | 1.71(1.40–2.09) | < 0.001 | 83.00% | < 0.001 | Random | |
| SCLC | 1 | – | – | – | – | – | |
| cut-off value | |||||||
| <300 × 10^9/L | 4 | 1.47(1.21–1.78) | 0.584 | 0.00% | 0.584 | Fixed | |
| 300 × 10^9/L ≤ cut-off value<400 × 10^9/L | 7 | 1.42(1.15–1.74) | < 0.001 | 81.40% | < 0.001 | Random | |
| ≥400 × 10^9/L | 2 | 3.30(2.52–4.32) | 0.383 | 0.00% | 0.383 | Fixed | |
| Quality score | |||||||
| > 6 | 11 | 1.77(1.42–2.20) | < 0.001 | 84.30% | < 0.001 | Random | |
| ≤6 | 2 | 1.04(0.85–1.26) | 0.114 | 0.599 | 0.114 | Fixed | |
OS Overall survival, DFS Disease-free survival, PFS Progress-free survival, TTP Time to progress, NSCLC Non-small cell lung cancer, SCLC Small cell lung cancer, HR Hazard ratio, CI Confidence interval